These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 30201235)

  • 1. Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.
    Zhao H; Yu H; Zheng J; Ning N; Tang F; Yang Y; Wang Y
    Gynecol Oncol; 2018 Nov; 151(2):345-355. PubMed ID: 30201235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA MALAT1 modified progression of clear cell kidney carcinoma (KIRC) by regulation of miR-194-5p/ACVR2B signaling.
    Ye Y; Zhang F; Chen Q; Huang Z; Li M
    Mol Carcinog; 2019 Feb; 58(2):279-292. PubMed ID: 30334578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. lncRNA MEG3 modified epithelial-mesenchymal transition of ovarian cancer cells by sponging miR-219a-5p and regulating EGFR.
    Wang L; Yu M; Zhao S
    J Cell Biochem; 2019 Oct; 120(10):17709-17722. PubMed ID: 31161607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
    Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
    Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205.
    Yang W; Hong L; Xu X; Wang Q; Huang J; Jiang L
    Tumour Biol; 2017 Jul; 39(7):1010428317711315. PubMed ID: 28671039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis.
    Zhang J; Yang ZM; Huang Y; Wang KN; Xie Y; Yang N
    Kaohsiung J Med Sci; 2021 Nov; 37(11):940-950. PubMed ID: 34414664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR-361-5p and FoxM1.
    Shen B; Zhou N; Hu T; Zhao W; Wu D; Wang S
    J Cell Physiol; 2019 Aug; 234(8):13464-13480. PubMed ID: 30624782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of LncRNA H19/miR-194-5p Axis on the Epithelial-Mesenchymal Transition of Colorectal Adenocarcinoma.
    Li CF; Li YC; Wang Y; Sun LB
    Cell Physiol Biochem; 2018; 50(1):196-213. PubMed ID: 30278464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA SNHG6 regulating Hedgehog signaling pathway and affecting the biological function of gallbladder carcinoma cells through targeting miR-26b-5p.
    Liu XF; Wang K; Du HC
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7598-7611. PubMed ID: 32744686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
    Zheng S; Li M; Miao K; Xu H
    J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR-486-5p and promoting neuropilin-2.
    Liu A; Liu L; Lu H
    J Cell Physiol; 2019 Aug; 234(8):13747-13761. PubMed ID: 30656681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.
    Liu XH; Lu KH; Wang KM; Sun M; Zhang EB; Yang JS; Yin DD; Liu ZL; Zhou J; Liu ZJ; De W; Wang ZX
    BMC Cancer; 2012 Aug; 12():348. PubMed ID: 22876840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p.
    Gao ZQ; Wang JF; Chen DH; Ma XS; Yang W; Zhe T; Dang XW
    Biomed Pharmacother; 2018 Jan; 97():809-817. PubMed ID: 29112934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative regulation of lncRNA GAS5 by miR-196a inhibits esophageal squamous cell carcinoma growth.
    Wang K; Li J; Xiong G; He G; Guan X; Yang K; Bai Y
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1151-1157. PubMed ID: 29170131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lncRNA GAS5 regulates myocardial infarction by targeting the miR-525-5p/CALM2 axis.
    Zhang Y; Hou YM; Gao F; Xiao JW; Li CC; Tang Y
    J Cell Biochem; 2019 Nov; 120(11):18678-18688. PubMed ID: 31429119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LINC-PINT suppresses tumour cell proliferation, migration and invasion through targeting miR-374a-5p in ovarian cancer.
    Hao T; Huang S; Han F
    Cell Biochem Funct; 2020 Dec; 38(8):1089-1099. PubMed ID: 32638404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ginsenoside 20(S)-Rg3 Prevents PKM2-Targeting miR-324-5p from H19 Sponging to Antagonize the Warburg Effect in Ovarian Cancer Cells.
    Zheng X; Zhou Y; Chen W; Chen L; Lu J; He F; Li X; Zhao L
    Cell Physiol Biochem; 2018; 51(3):1340-1353. PubMed ID: 30481782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA LUCAT1 promotes proliferation of ovarian cancer cells by regulating miR-199a-5p expression.
    Liu HZ; Liu GY; Pang WW; Zhang H; Zeng ZJ; Wang HJ
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1682-1687. PubMed ID: 32141534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion, and indicates a poor prognosis in ovarian cancer.
    Li J; Huang H; Li Y; Li L; Hou W; You Z
    Oncol Rep; 2016 Dec; 36(6):3241-3250. PubMed ID: 27779700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.